We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 24, 2023 – Today, Zacks Investment Ideas feature highlights Fresenius Medical Care (FMS - Free Report) , Vericel (VCEL - Free Report) and ImmunoGen .
Top Medical Stocks to Buy Amid Recent Market Volatility
Recent volatility in the stock market has been fueled by the 10-Year Treasury Yield rising over the last few weeks and still hovering near 5%.
Fear may be settling in as Bearish pundits start to make their case. However, several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.
Fresenius Medical Care: Speaking to the essentiality of healthcare, Fresenius Medical Care's stock is starting to look attractive even with global economic fears still prevalent. Based in Germany, Fresenius is one of the largest integrated providers of dialysis products and services for chronic kidney failure.
Notably, fiscal 2023 and FY24 earnings estimates have remained higher over the last 60 days with Fresenius' stock trading attractively at 13.4X forward earnings. Annual earnings are forecasted to dip -21% in FY23 at $1.30 per share following a tough-to-compete-against year but rebound and soar 23% in FY24 to $1.60 a share.
Plus, sales are projected to be up 5% this year and rise another 3% in FY24 to $21.97 billion. Fresenius also offers a generous 2.35% annual dividend yield with shares of FMS still up a respectable +5% in 2023.
Vericel: Soaring +28% this year, Vericel Corporation's stock stands out and investors may be eager to buy VCEL shares on the dip. Focused on developing patient-specific expanded cell therapies used in the treatment of severe diseases/conditions, Vericel's top-line expansion largely points to its future earnings potential.
Catapulting Vericel's stock, sales are forecasted to jump 19% this year and climb another 24% in FY24 to $243.44 million. More intriguing, with earnings estimates on the rise the company is expecting a smaller adjusted loss of -$0.23 a share in FY23 with EPS forecasted to climb into the black at $0.08 per share in FY24.
ImmunoGen: Lastly, ImmunoGen's stock has skyrocketed +157% YTD and is a very enticing buy-the-dip candidate with IMGN shares trading at $12 and 38% from 52-week highs of $20 per share seen in July.
The very strong price performance in ImmunoGen stock has been attributed to a strengthening outlook as a biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology.
Annual earnings estimates have soared throughout the quarter with FY23 EPS anticipated at an adjusted loss of -$0.10 a share compared to -$0.88 per share last year. Fiscal 2024 earnings are now expected to leap into the black at $0.19 per share. Furthermore, sales are expected at $340.39 million this year compared to $108.78 million in 2022 with ImmunoGen's top line projected to expand another 45% in FY24 to $493.74 million.
Bottom Line
Given the strengthening outlook of these healthcare stocks they currently have an "A" Zacks Style Scores grade for Momentum in addition to their Zacks Rank #1 (Strong Buy). The trend of rising earnings estimate revisions is compelling and makes Fresenius Medical Care, Vericel, and ImmunoGen's stock very attractive at the moment with the broader medical sector generally being an ideal place to hide out during market volatility.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen
For Immediate Release
Chicago, IL – October 24, 2023 – Today, Zacks Investment Ideas feature highlights Fresenius Medical Care (FMS - Free Report) , Vericel (VCEL - Free Report) and ImmunoGen .
Top Medical Stocks to Buy Amid Recent Market Volatility
Recent volatility in the stock market has been fueled by the 10-Year Treasury Yield rising over the last few weeks and still hovering near 5%.
Fear may be settling in as Bearish pundits start to make their case. However, several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.
Fresenius Medical Care: Speaking to the essentiality of healthcare, Fresenius Medical Care's stock is starting to look attractive even with global economic fears still prevalent. Based in Germany, Fresenius is one of the largest integrated providers of dialysis products and services for chronic kidney failure.
Notably, fiscal 2023 and FY24 earnings estimates have remained higher over the last 60 days with Fresenius' stock trading attractively at 13.4X forward earnings. Annual earnings are forecasted to dip -21% in FY23 at $1.30 per share following a tough-to-compete-against year but rebound and soar 23% in FY24 to $1.60 a share.
Plus, sales are projected to be up 5% this year and rise another 3% in FY24 to $21.97 billion. Fresenius also offers a generous 2.35% annual dividend yield with shares of FMS still up a respectable +5% in 2023.
Vericel: Soaring +28% this year, Vericel Corporation's stock stands out and investors may be eager to buy VCEL shares on the dip. Focused on developing patient-specific expanded cell therapies used in the treatment of severe diseases/conditions, Vericel's top-line expansion largely points to its future earnings potential.
Catapulting Vericel's stock, sales are forecasted to jump 19% this year and climb another 24% in FY24 to $243.44 million. More intriguing, with earnings estimates on the rise the company is expecting a smaller adjusted loss of -$0.23 a share in FY23 with EPS forecasted to climb into the black at $0.08 per share in FY24.
ImmunoGen: Lastly, ImmunoGen's stock has skyrocketed +157% YTD and is a very enticing buy-the-dip candidate with IMGN shares trading at $12 and 38% from 52-week highs of $20 per share seen in July.
The very strong price performance in ImmunoGen stock has been attributed to a strengthening outlook as a biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology.
Annual earnings estimates have soared throughout the quarter with FY23 EPS anticipated at an adjusted loss of -$0.10 a share compared to -$0.88 per share last year. Fiscal 2024 earnings are now expected to leap into the black at $0.19 per share. Furthermore, sales are expected at $340.39 million this year compared to $108.78 million in 2022 with ImmunoGen's top line projected to expand another 45% in FY24 to $493.74 million.
Bottom Line
Given the strengthening outlook of these healthcare stocks they currently have an "A" Zacks Style Scores grade for Momentum in addition to their Zacks Rank #1 (Strong Buy). The trend of rising earnings estimate revisions is compelling and makes Fresenius Medical Care, Vericel, and ImmunoGen's stock very attractive at the moment with the broader medical sector generally being an ideal place to hide out during market volatility.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.